Contra-indicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C).
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Zepatier (Merck)
- INDICATIONS: Chronic hepatitis C virus genotypes 1 or 4 (with or without ribavirin)
- CLASS: Direct-acting antiviral, Hepatitis C virus NS3/4A protease inhibitor (grazoprevir), Hepatitis C virus NS5A inhibitor (elbasvir)
- HALF-LIFE: 24 hours (elbasvir); 31 hours (grazoprevir)
- FDA APPROVAL DATE: 01/28/2016
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atazanavir, Atorvastatin, Bosentan, Carbamazepine, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Cyclosporine, Darunavir, Efavirenz, Fluvastatin, Ketoconazole, Lopinavir, Lovastatin, Modafinil, Moderate CYP3A inducers, Nafcillin, OATP1B1/3 inhibitors, Phenytoin, Rifampin, Rosuvastatin, Saquinavir, Simvastatin, Strong CYP3A inducers, Tacrolimus, Tipranavir - PREGNANCY: No available data; contra-indicated in pregnant women and in men with pregnant partners when administered with ribavirin
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of elbasvir & grazoprevir in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
